THE ALTASCIENTIST Our two latest editions of The Altascientist are now available! They focus on biosmilars and metabolic disorders, including Diabetes and Nonalcoholic Fatty Liver Disease (NAFLD). REQUEST YOUR COPY The number of clinical trials for biosimilars has increased almost eightfold between 2007 and 2014. Issue No. 4 of The Altascientist explores our vast experience with biosimilar studies and lists the key considerations Altasciences urges sponsors to take into account before beginning a clinical study for these types of drugs. REQUEST YOUR COPY Metabolic disorders can take many forms, with obesity, diabetes and most recently, NAFLD, being characterized as global epidemics. In issue No. 5 of The Altascientist, we discuss Altasciences’ therapeutic offerings in gastrointestinal disease-specific studies, with a particular focus on diabetes and NAFLD, including a recent case study.